ATE293991T1 - VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN - Google Patents

VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN

Info

Publication number: ATE293991T1
Authority: AT; Austria
Prior art keywords: melanoma; ßelagigiltvß; enterobacterial; peptide; treatment
Prior art date: 1999-02-17

Application number

AT00906412T

Other languages

English (en)

Inventor

Toufic Renno

Pedro Romero

Isabelle Miconnet

Jean-Charles Carottini

Jean-Yves Bonnefoy

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-17

Filing date

2000-02-17

Publication date

2005-05-15

2000-02-17 Application filed by Pf Medicament filed Critical Pf Medicament

2005-05-15 Application granted granted Critical

2005-05-15 Publication of ATE293991T1 publication Critical patent/ATE293991T1/de

Links

201000001441 melanoma Diseases 0.000 title abstract 2
241000305071 Enterobacterales Species 0.000 title 1
SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical compound CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
241000588747 Klebsiella pneumoniae Species 0.000 abstract 1
108010079246 OMPA outer membrane proteins Proteins 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1
230000001173 tumoral effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/26—Klebsiella (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00906412T 1999-02-17 2000-02-17 VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN ATE293991T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9901917A FR2789588B1 (fr)	1999-02-17	1999-02-17	Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale
PCT/FR2000/000394 WO2000048629A1 (fr)	1999-02-17	2000-02-17	UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE ASSOCIEE AU PEPTIDE ELAGIGILTV POUR LE TRAITEMENT DES MELANOMES

Publications (1)

Publication Number	Publication Date
ATE293991T1 true ATE293991T1 (de)	2005-05-15

Family

ID=9542129

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00906412T ATE293991T1 (de)	1999-02-17	2000-02-17	VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN

Country Status (11)

Country	Link
EP (2)	EP1150706A1 (de)
JP (2)	JP2003506315A (de)
CN (2)	CN1191089C (de)
AT (1)	ATE293991T1 (de)
AU (2)	AU777511B2 (de)
BR (2)	BR0008307A (de)
CA (2)	CA2362192A1 (de)
DE (1)	DE60019725D1 (de)
FR (1)	FR2789588B1 (de)
WO (2)	WO2000048628A1 (de)
ZA (2)	ZA200106725B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2803302B1 (fr) *	2000-01-04	2004-12-10	Pf Medicament	Procede de preparation d'un polypeptide soluble en solvant aqueux en absence de detergent
FR2808445A1 (fr) *	2000-05-04	2001-11-09	Pf Medicament	Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues
FR2842812A1 (fr) *	2002-07-26	2004-01-30	Pf Medicament	Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
WO2004011486A2 (fr) *	2002-07-26	2004-02-05	Pierre Fabre Medicament	Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse
FR2842811A1 (fr) *	2002-07-26	2004-01-30	Pf Medicament	Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
JP5151349B2 (ja) *	2006-09-26	2013-02-27	東レ株式会社	免疫誘導剤及びその用途
EP2377883A1 (de) *	2010-04-15	2011-10-19	Universite d'Auvergne Clermont I	Antagonisten zur Vorbeugung oder Behandlung von entzündlicher Darmerkrankung, speziell von Morbus Crohn
WO2011140284A2 (en) *	2010-05-04	2011-11-10	Fred Hutchinson Cancer Research Center	Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
CN110559424B (zh) *	2019-08-26	2021-08-20	君维安(武汉)生命科技有限公司	一种外膜蛋白在制备恶性肿瘤免疫治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2726472B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2748476B1 (fr) *	1996-05-07	1998-08-14	Pf Medicament	Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant

1999
- 1999-02-17 FR FR9901917A patent/FR2789588B1/fr not_active Expired - Fee Related
2000
- 2000-02-17 JP JP2000599419A patent/JP2003506315A/ja active Pending
- 2000-02-17 CN CNB008039593A patent/CN1191089C/zh not_active Expired - Fee Related
- 2000-02-17 AU AU28093/00A patent/AU777511B2/en not_active Ceased
- 2000-02-17 AU AU28094/00A patent/AU776903B2/en not_active Ceased
- 2000-02-17 BR BR0008307-0A patent/BR0008307A/pt not_active IP Right Cessation
- 2000-02-17 WO PCT/FR2000/000393 patent/WO2000048628A1/fr not_active Ceased
- 2000-02-17 EP EP00906411A patent/EP1150706A1/de not_active Withdrawn
- 2000-02-17 AT AT00906412T patent/ATE293991T1/de not_active IP Right Cessation
- 2000-02-17 DE DE60019725T patent/DE60019725D1/de not_active Expired - Lifetime
- 2000-02-17 EP EP00906412A patent/EP1150707B1/de not_active Expired - Lifetime
- 2000-02-17 CN CNB008050937A patent/CN1191090C/zh not_active Expired - Fee Related
- 2000-02-17 WO PCT/FR2000/000394 patent/WO2000048629A1/fr not_active Ceased
- 2000-02-17 CA CA002362192A patent/CA2362192A1/fr not_active Abandoned
- 2000-02-17 BR BR0008305-4A patent/BR0008305A/pt not_active IP Right Cessation
- 2000-02-17 CA CA002372059A patent/CA2372059A1/fr not_active Abandoned
- 2000-02-17 JP JP2000599418A patent/JP2003506314A/ja active Pending
2001
- 2001-08-15 ZA ZA200106725A patent/ZA200106725B/xx unknown
- 2001-08-17 ZA ZA200106800A patent/ZA200106800B/en unknown

Also Published As

Publication number	Publication date
WO2000048629A1 (fr)	2000-08-24
AU2809400A (en)	2000-09-04
BR0008305A (pt)	2002-01-22
BR0008307A (pt)	2002-01-22
FR2789588A1 (fr)	2000-08-18
FR2789588B1 (fr)	2001-05-04
JP2003506315A (ja)	2003-02-18
CA2362192A1 (fr)	2000-08-24
AU777511B2 (en)	2004-10-21
CN1191089C (zh)	2005-03-02
ZA200106800B (en)	2002-05-10
JP2003506314A (ja)	2003-02-18
AU776903B2 (en)	2004-09-23
CN1344166A (zh)	2002-04-10
ZA200106725B (en)	2002-04-24
EP1150706A1 (de)	2001-11-07
CA2372059A1 (fr)	2000-08-24
EP1150707B1 (de)	2005-04-27
EP1150707A1 (de)	2001-11-07
AU2809300A (en)	2000-09-04
WO2000048628A1 (fr)	2000-08-24
DE60019725D1 (de)	2005-06-02
CN1341029A (zh)	2002-03-20
CN1191090C (zh)	2005-03-02

Legal Events

Date	Code	Title	Description
2005-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
MY136095A (en)	2008-08-29	Use of human anti-ctla-4 antibodies for treatment of cancer
TR200301846T2 (tr)	2006-10-26	Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE265456T1 (de)	2004-05-15	2-amino-6-anilino-purine und deren verwendung als arzneimittel
IL147271A (en)	2014-07-31	Isolated peptide ligands that bind to her2
BR9811956B1 (pt)	2010-06-01	naftiridinonas e composição farmacêutica compreendendo as mesmas.
EP1015008A4 (de)	2006-08-09	Verbindungen und zusammensetzungen zur administration aktiver stoffe
MY155218A (en)	2015-09-30	Small molecules useful in the treatment of inflammatory disease
IL176007A0 (en)	2006-10-05	Antibodies specific to c35 and pharmaceutical compositions containing the same
YU68702A (sh)	2006-01-16	Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
ATE293991T1 (de)	2005-05-15	VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN
WO2003017939A3 (en)	2003-11-13	Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
ATE325803T1 (de)	2006-06-15	Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
TR200100637T2 (tr)	2001-10-22	Yeni doğal ürün türevleri
IL149416A0 (en)	2002-11-10	Human enzymes of the metalloprotease family
DE60123117D1 (de)	2006-10-26	Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
ATE408619T1 (de)	2008-10-15	Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
AU2001235761A1 (en)	2001-09-03	Diagnosis of breast cancer using bcmp-11 as marker
DE60008077D1 (de)	2004-03-11	Matrixprotein zusammensetzungen um apoptose zu induzieren
MXPA02010813A (es)	2004-02-26	Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor.
DE50200757D1 (de)	2004-09-09	Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
WO2006010838A3 (fr)	2006-06-15	Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant
IL164356A (en)	2010-11-30	Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
ATE397003T1 (de)	2008-06-15	Ruthenium(ii)-komplexe zur behandlung von tumoren
AU2001256440A1 (en)	2001-11-12	Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
WO2003076651A3 (en)	2004-02-05	Cancer associated araf1 protein kinase and its uses